EU, US & Japan Tackle Difficulties With Randomized Trials Involving Multi-Drug Resistant Bacteria
Executive Summary
The European Medicines Agency has given the Pink Sheet more detail on its recent agreement with its counterparts in the US and Japan to align certain clinical data requirement to stimulate the development of new treatments to fight antimicrobial resistance.
You may also be interested in...
Faster AMR Drug Reviews And A New Pathogen List On Health Canada’s Agenda
Health Canada is seeking comments on a proposed list of pathogens that is designed to help the government department understand how it can stimulate the submission of new drugs for beating antimicrobial resistance and facilitate their regulatory approval.
Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances
Regulatory incentives have been successful at attracting developers to antibiotic R&D, but significant medical advances have stubbornly remained rare. Now the pipeline has produced the first novel antibiotic to receive breakthrough status from US FDA and some Phase III trials are raising the efficacy bar to superiority.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.